MedTrace Logo

Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis

NCT05324163 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2023-03-07

No results posted yet for this study

Summary

This study is a randomized, double-blind clinical trial in a Chinese population

Conditions

Interventions

DRUG

X0002 Spray

X0002 spray 17.5mg, twice a day; Celecoxib placebo 200mg, once a day

DRUG

Celecoxib capsules

X0002 spray placebo 17.5 mg, twice a day; Celecoxib capsule 200mg, once a day

DRUG

placebo

X0002 spray placebo 17.5 mg, twice a day; Celecoxibplacebo 200mg, once a day

Sponsors & Collaborators

  • Jiangsu XinChen-Techfields Pharma Co., LTD.

    lead INDUSTRY

Principal Investigators

  • xiaofeng zeng · Study Principal Investigator

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-29
Primary Completion
2023-02-06
Completion
2023-02-06

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05324163 on ClinicalTrials.gov